Inokumodareyitha ukungonakaliswa kwamalungu amadolo
Iziphumo zoFundo ezichazwe kwimiba ye- Arthritis neRheumatism yaphakamisa ukuba unyango kunye ne-antixytic doxycycline lunganciphisa ukuqhubela phambili kwe- osteoarthritis . I-Doxycycline yintsholongwane yeklasi ebizwa ngokuba yi-tetracyclines.
Ngomxholo we-Doxycycline ka-2005
Abaphandi baqhathanisa ukusebenzisa i-doxycycline kwindawo ye-placebo, emva kokubhalisa abangaphezu kwama-400 abesetyhini abane- arthritis emadolweni njengabantu abathatha isifundo.
Abafundi abathathi-nxaxheba babekwa ngamaqela amabini, befumana i-100 mg ye-doxycycline kabini imihla ngemihla okanye indawo ye-placebo eneminyaka engama-2.5. Abaphengululi bahlalutye umphumo we doxycycline kwindawo edibeneyo yegciwane elichaphazelekayo.
Ukulandela inyanga ezili-16 zonyango, iziphumo zibonise ukuba ukulahleka okuqhelekileyo kwendawo edibeneyo kwidolo elichaphazelekayo bekulingama-40% ngaphantsi kwabathathi-nxaxheba abathatha i-doxycycline kunabo bawathatha indawo ye-placebo. Ekupheleni kwexesha lesibini kunye nesiqingatha sonyaka, ukulahlekelwa kwendawo edibeneyo yayingu-33% ngaphantsi kwiqela elithatha i-doxycyline kuneqela le-placebo. I-Doxycycline yadibaniswa nokunyuka kwengxelo engaphantsi kwesigulane kwiintlungu zamadolo. Abaphengululi bavuma ke, ukuba izinga eliqhelekileyo lentlungu liphantsi kumaqela amabini.
Uphononongo luka-2005 ngowokuqala uhlolisiso lwe doxycycline njengokuba unyango lwe-osteoarthritis. Ngelo xesha, kwathiwa kufuneka kwenziwe uphando olongezelelweyo ukuqinisekisa iziphumo.
Iingxelo ezivela kuDkt. Zashin
Ngomxholo we-doxycycline kunye ne-osteoarthritis, i-rheumatologist uScott Zashin, u-MD wathi, "Okokuqala, lo luhlolisiso oluyingqayizivele kwinto yokuba ifunyenwe ixesha elide elijonge amayeza ukuba angagcini nje ukukhulula intlungu, kodwa inokuthintela ukuqhubela phambili ye-osteoarthritis yamadolo.
Nangona uphando aluzange lubonise ngokucacileyo ukuba i-doxycycline yomlomo yayiphumelele ekunciphiseni intlungu, bekukho ubungqina bokuthi kukho ukunyuka kwe-osteoarthritis (oko kukuthi, ukulahlekelwa kwe-cartilage encinane) kwizigulane kwi-antibiotic. Ababhali benza ukuba kucace ukuba i-antibiotics yayivakala ukuba isebenze ngokusekelwe kwiipropati zayo ezichasayo , kungekhona ngenxa yempembelelo yayo yokulwa ne-antibacterial. "
UDkt. Zashin waqhubeka wathi, "Yintoni le nto ithetha ngayo kwizigulane ezine-osteoarthritis? Imiba emibini yokwelapha ibalulekile kwizigulane kunye noogqirha kubandakanya ukuba iyeza liyakuthintela ngokungahambi kakuhle kwaye ingaba isiguli singasidinga ukutshintshwa ngokubambisana kwixesha elizayo. , kunzima ukucebisa i-doxycyline yangexesha elide ukwenzela ukukhululeka kweempawu . Ngakolunye uhlangothi, kunokwenzeka ukuba izigulane ezithatha i-antibiotiki zingenakunokwenzeka ukuba zifune ukutshintshwa ngokubambisana ngexesha elizayo ngenxa yokunciphisa umonakalo odibeneyo kwi-radiograph. Ngelishwa, ukuba uphendule lo mbuzo, kwakufuneka kufundwe ixesha elide. Enye imibuzo ekufuneka uyiqwalasele ukuba ingaba izigulane ziza kufuneka zihlale kwii-antibiotics ngonaphakade ukuze zinciphise umonakalo ohlanganyelweyo kwaye zithintele ukutshintshwa ngokubambisana kunye neziphumo ezimbi ezivela kule regimen yekota.
Omnye umbuzo wukuthi unyango lwenyanga engama-30 kunye neziyobisi, ngokwalo, kunciphisa amathuba okuba ekuhambeni kwexesha, ezo zigulane ziza kuba nzima ukufuna ukuhlinzwa. Ngethemba, eli qela lazigulane liyakwazi ukuqhubeka lifundiswa kwixesha elizayo ukunceda ukuphendula imibuzo. "
Uhlolo lwe-Cochrane ka-2012 lwe-Doxycycline kwi-Osteoarthritis
Ngo-2012, ukuhlaziywa kwanyatheliswa ngokuhlolwa kweCorrane ye-doxycycline ye-osteoarthritis ekuqaleni eyapapashwa ngo-2009. Ukuhlaziywa kwakuqwalaselwe ubungqina kwiincwadi zonyango ezaziye zahlola imiphumo ye-doxycycline kwiintlungu kunye nokusebenza ngokomzimba kwizigulane ezine-osteoarthritis ye-hip okanye idolo xa kuthelekiswa kwindawo yokubeka indawo.
Kufunyenwe kuphela izifundo ezimbini ezibandakanya abantu abangama-663 ezifanelekileyo kwaye zibandakanywe ekuhlaziyweni. Uphononongo luphelile ukuba umphumo we doxycycline kwiimpawu zeentlungu ze-osteoarthritis ayikho impawu ezibalulekileyo zonyango. Abafundi abathathi-nxaxheba babala ukuphuculwa kwentlungu njengoko i-1.9 kwinqanaba le-0 (akukho buhlungu) ukuya kwi-10 (intlungu ebuhlungu) xa kuthelekiswa nokuphuculwa kweengongoma eziyi-1.8 zezigulane ze-placebo emva kweenyanga ezili-18.
Iziphumo zokuphononongwa kwakhona zibonise ukuba umphumo we doxycycline kumsebenzi wenyama wawungabalulekanga kwiiklinikhi. Ukuphuculwa komsebenzi wezinto eziphathekayo kwakungama-1.4 kuphela ukuya kuma-1.2 amaphuzu kwinqanaba le-10 kubafundi abathatha inxaxheba kwi-doxycycline kunye ne-placebo, ngokulandelanayo.
Kwakhona kwaphawulwa ekuhlaziyweni ukuba i-20% yabathathi-nxaxheba abathatha i-doxycycline kwimiphumo emibi (nayiphi na uhlobo) xa kuthelekiswa ne-15% yabathathi bendawo. Ekugqibeleni, inzuzo ye-doxycycline ephathelele ukulahlekelwa kwendawo edibeneyo eyayibikwa ekuqaleni yabonwa njengento encinci kunye nokuchaphazeleka kweklinikhi ekuhlaziyweni kweCchrane.
> Imithombo:
> Iimpembelelo ze-Doxycycline ekuqhubekeni kwe-Osteoarthritis: Iziphumo ze-Randomized, i-Placebo-Controlled, i-Tri-Blind Trial. Brandt KD et al. Arthritis & Rheumatology. Julayi 2005.
> I-Doxycycline ye-Osteoarthritis ye-Knee okanye i-Hip. da Costa BR et al. Library yaseCchrane. Novemba 2012.